What are the major opportunities in the Human Immunodeficiency Virus Therapeutics market? What are the strategies for the Human Immunodeficiency Virus Therapeutics market?

For detailed insights on the major opportunities and strategies in the Human Immunodeficiency Virus Therapeutics market, Read More

How does the Human Immunodeficiency Virus Therapeutics market relate to the overall economy and other similar markets?

For detailed insights on Human Immunodeficiency Virus Therapeutics's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Human Immunodeficiency Virus Therapeutics market growth? SWOT analysis of the Human Immunodeficiency Virus Therapeutics market.

For detailed insights on the key dynamics influencing the Human Immunodeficiency Virus Therapeutics market growth and SWOT analysis of the Human Immunodeficiency Virus Therapeutics industry, Read More

Global Human Immunodeficiency Virus Therapeutics Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

Human Immunodeficiency Virus Therapeutics Global Market Report 2025

Name: Human Immunodeficiency Virus Therapeutics Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Type (Branded Drugs, Generic Drugs), By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Entry And Fusion Inhibitors, Protease Inhibitors (Pis), Integrase Inhibitors, Coreceptor Antagonists), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By End-user (Hospitals And Clinics, Specialty Centers) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Human Immunodeficiency Virus Therapeutics Market Overview

• Human Immunodeficiency Virus Therapeutics market size has reached to $14.11 billion in 2024

• Expected to grow to $18.44 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%

• Growth Driver: Increase In Unprotected Sexual Practices Fueling The Market Due To Limited Access To Contraception And Lack Of Comprehensive Sex Education

• Market Trend: Focus On Combination Therapy For Improved Treatment Outcomes

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Immunodeficiency Virus Therapeutics Market?

Human immunodeficiency virus (HIV) therapeutics refer to medications and treatment strategies designed to manage and suppress HIV infection, primarily through antiretroviral therapy (ART). These therapeutics help reduce viral load, prevent disease progression to AIDS, and improve the quality of life for individuals living with HIV.

The main drug types of human immunodeficiency virus therapeutics are branded drugs and generic drugs. Branded drugs are patented medicines developed and sold under a unique name, undergoing rigorous research and clinical trials to ensure safety and effectiveness. The drug classes include nucleoside-analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, protease inhibitors (PIs), integrase inhibitors, and coreceptor antagonists. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies and are used by end users such as hospitals, clinics, and specialty centers.

Human Immunodeficiency Virus Therapeutics Market Size and growth rate 2025 to 2029: Graph

What Is The Human Immunodeficiency Virus Therapeutics Market Size 2025 And Growth Rate?

What Is The Human Immunodeficiency Virus Therapeutics Market Growth Forecast?

The human immunodeficiency virus therapeutics market size is expected to see strong growth in the next few years. It will grow to $18.44 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising HIV patient pool, increasing HIV screening, increase in voluntary testing, surge in unprotected sex practices, and expansion of government programs. Major trends in the forecast period include technological advancements, AI-driven drug discovery, long-acting injectable therapies, telemedicine integration, and CRISPR-based gene therapy.

The forecast of 5.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S.by increasing the cost of antiretroviral drugs and long-acting injectable HIV treatments sourced from India and Ireland, thereby reducing medication adherence and elevating infectious disease management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Human Immunodeficiency Virus Therapeutics Market Segmented?

1) By Drug Type: Branded Drugs, Generic Drugs

2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Entry And Fusion Inhibitors, Protease Inhibitors (Pis), Integrase Inhibitors, Coreceptor Antagonists

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

4) By End-user: Hospitals And Clinics, Specialty Centers

Subsegments:

1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista

2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir

What Is Driving The Human Immunodeficiency Virus Therapeutics Market? Increase In Unprotected Sexual Practices Fueling The Market Due To Limited Access To Contraception And Lack Of Comprehensive Sex Education

The growing prevalence of unprotected sexual practices is expected to propel the growth of the human immunodeficiency virus therapeutics market going forward. Unprotected sexual practices refer to sexual activities without barrier protection, increasing the risk of sexually transmitted infections (STIs) and unintended pregnancies. Lack of comprehensive sex education leads to limited awareness about safe practices, which increases risky behavior among youth. Human immunodeficiency virus therapeutics help reduce the risk of HIV transmission from unprotected sexual practices by suppressing viral load to undetectable levels, preventing further spread of the infection. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in a 2023 survey of U.S. high school students, 32% reported having had sexual intercourse at least once, and 48% stated that they did not use a condom during their most recent sexual encounter. Therefore, the growing prevalence of unprotected sexual practices is driving the growth of the human immunodeficiency virus therapeutics industry.

Who Are The Major Players In The Global Human Immunodeficiency Virus Therapeutics Market?

Major companies operating in the human immunodeficiency virus therapeutics market are Pfizer Inc., Johnson & Johnson, F Hoffmann La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company (BMS), Novartis International AG, GlaxoSmithKline plc (GSK), Gilead Sciences Inc., Moderna Inc., BioNTech SE, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hetero Labs Limited, Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research), Vir Biotechnology Inc., Theratechnologies Inc., CytoDyn Inc.

What Are The Key Trends Of The Global Human Immunodeficiency Virus Therapeutics Market? Focus On Combination Therapy For Improved Treatment Outcomes

Major companies operating in the human immunodeficiency virus (HIV) therapeutics market are focusing on developing innovative treatments, such as combination therapy, to improve treatment efficacy, reduce drug resistance, and enhance patient adherence. Combination therapy involves the use of two or more therapeutic agents, including drugs or other treatments, to manage a single disease or condition. This approach enhances treatment effectiveness, minimizes side effects, and lowers the risk of drug resistance. For instance, in December 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Sunlenca (lenacapavir). This treatment, used in combination with other antiretroviral medications, is designed for adults with multi-drug-resistant HIV-1. Sunlenca is notable for being the first and only HIV treatment based on a capsid inhibitor, offering a dosing option of twice a year for patients who have undergone extensive treatment. The approval is supported by the CAPELLA trial, which showed high rates of sustained virologic suppression. With its innovative mechanism of action and long-acting formulation, Sunlenca is anticipated to play a key role in future HIV treatment and prevention strategies.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Human Immunodeficiency Virus Therapeutics Market? F. Hoffmann-La Roche Ltd. Partners With The Global Fund To Strengthen HIV And Tuberculosis Diagnosis In Low- And Middle-Income Countries

In May 2022, F. Hoffmann-La Roche Ltd., a Switzerland-based biopharmaceutical and diagnostic company, partnered with the Global Fund to enhance diagnostic capabilities and strengthen pandemic preparedness in low- and middle-income countries. The collaboration aims to expand access to HIV and tuberculosis testing, address infrastructure challenges, and improve healthcare waste management. The Global Fund is a Switzerland-based global financing and partnership organization that provides grants for HIV/AIDS healthcare systems.

What Is The Regional Outlook For The Global Human Immunodeficiency Virus Therapeutics Market?

North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Immunodeficiency Virus Therapeutics Market?

The human immunodeficiency virus therapeutics market consists of revenues earned by entities by providing services such as telehealth and remote patient monitoring, patient support and case management services, clinical trials and research services, and HIV testing and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human immunodeficiency virus therapeutics market also includes sales of antiretroviral drugs (ARVs), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and immune system boosters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Human Immunodeficiency Virus Therapeutics Industry?

The human immunodeficiency virus therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human immunodeficiency virus therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Human Immunodeficiency Virus Therapeutics Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$14.9 billion
Revenue Forecast In 2034	$18.44 billion
Growth Rate	CAGR of 5.5% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The human immunodeficiency virus therapeutics market covered in this report is segmented – 1) By Drug Type: Branded Drugs, Generic Drugs 2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Entry And Fusion Inhibitors, Protease Inhibitors (Pis), Integrase Inhibitors, Coreceptor Antagonists 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies 4) By End-user: Hospitals And Clinics, Specialty Centers Subsegments: 1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista 2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Request for Sample
Customization Scope	Explore Purchase Options
Pricing And Purchase Options

1. Executive Summary

2. Human Immunodeficiency Virus Therapeutics Market Characteristics

3. Human Immunodeficiency Virus Therapeutics Market Trends And Strategies

4. Human Immunodeficiency Virus Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Human Immunodeficiency Virus Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Human Immunodeficiency Virus Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Human Immunodeficiency Virus Therapeutics Market Growth Rate Analysis

5.4. Global Human Immunodeficiency Virus Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Human Immunodeficiency Virus Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Human Immunodeficiency Virus Therapeutics Total Addressable Market (TAM)

6. Human Immunodeficiency Virus Therapeutics Market Segmentation

6.1. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Branded Drugs

Generic Drugs

6.2. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis)

Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)

Entry And Fusion Inhibitors

Protease Inhibitors (Pis)

Integrase Inhibitors

Coreceptor Antagonists

6.3. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

6.4. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals And Clinics

Specialty Centers

6.5. Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Branded Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Biktarvy

Triumeq

Genvoya

Juluca

Dovato

Isentress

Prezista

6.6. Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tenofovir Disoproxil Fumarate (TDF)

Lamivudine

Efavirenz

Zidovudine

Nevirapine

Abacavir

Ritonavir

7. Human Immunodeficiency Virus Therapeutics Market Regional And Country Analysis

7.1. Global Human Immunodeficiency Virus Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Human Immunodeficiency Virus Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market

8.1. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Immunodeficiency Virus Therapeutics Market

9.1. China Human Immunodeficiency Virus Therapeutics Market Overview

9.2. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Immunodeficiency Virus Therapeutics Market

10.1. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Immunodeficiency Virus Therapeutics Market

11.1. Japan Human Immunodeficiency Virus Therapeutics Market Overview

11.2. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Immunodeficiency Virus Therapeutics Market

12.1. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Immunodeficiency Virus Therapeutics Market

13.1. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Immunodeficiency Virus Therapeutics Market

14.1. South Korea Human Immunodeficiency Virus Therapeutics Market Overview

14.2. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Immunodeficiency Virus Therapeutics Market

15.1. Western Europe Human Immunodeficiency Virus Therapeutics Market Overview

15.2. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Immunodeficiency Virus Therapeutics Market

16.1. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Immunodeficiency Virus Therapeutics Market

17.1. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Immunodeficiency Virus Therapeutics Market

18.1. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Immunodeficiency Virus Therapeutics Market

19.1. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Immunodeficiency Virus Therapeutics Market

20.1. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Immunodeficiency Virus Therapeutics Market

21.1. Eastern Europe Human Immunodeficiency Virus Therapeutics Market Overview

21.2. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Immunodeficiency Virus Therapeutics Market

22.1. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Immunodeficiency Virus Therapeutics Market

23.1. North America Human Immunodeficiency Virus Therapeutics Market Overview

23.2. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Immunodeficiency Virus Therapeutics Market

24.1. USA Human Immunodeficiency Virus Therapeutics Market Overview

24.2. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Immunodeficiency Virus Therapeutics Market

25.1. Canada Human Immunodeficiency Virus Therapeutics Market Overview

25.2. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Immunodeficiency Virus Therapeutics Market

26.1. South America Human Immunodeficiency Virus Therapeutics Market Overview

26.2. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Immunodeficiency Virus Therapeutics Market

27.1. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Immunodeficiency Virus Therapeutics Market

28.1. Middle East Human Immunodeficiency Virus Therapeutics Market Overview

28.2. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Immunodeficiency Virus Therapeutics Market

29.1. Africa Human Immunodeficiency Virus Therapeutics Market Overview

29.2. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Immunodeficiency Virus Therapeutics Market Competitive Landscape And Company Profiles

30.1. Human Immunodeficiency Virus Therapeutics Market Competitive Landscape

30.2. Human Immunodeficiency Virus Therapeutics Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. F Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Human Immunodeficiency Virus Therapeutics Market Other Major And Innovative Companies

31.1. Sanofi SA

31.2. Bristol Myers Squibb Company (BMS)

31.3. Novartis International AG

31.4. GlaxoSmithKline plc (GSK)

31.5. Gilead Sciences Inc.

31.6. Moderna Inc.

31.7. BioNTech SE

31.8. Teva Pharmaceutical Industries Ltd.

31.9. Boehringer Ingelheim International GmbH

31.10. Aurobindo Pharma Limited

31.11. Cipla Limited

31.12. Hetero Labs Limited

31.13. Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research)

31.14. Vir Biotechnology Inc.

31.15. Theratechnologies Inc.

32. Global Human Immunodeficiency Virus Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Immunodeficiency Virus Therapeutics Market

34. Recent Developments In The Human Immunodeficiency Virus Therapeutics Market

35. Human Immunodeficiency Virus Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Human Immunodeficiency Virus Therapeutics Market In 2029 - Countries Offering Most New Opportunities

35.2 Human Immunodeficiency Virus Therapeutics Market In 2029 - Segments Offering Most New Opportunities

35.3 Human Immunodeficiency Virus Therapeutics Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Branded Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Human Immunodeficiency Virus Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Human Immunodeficiency Virus Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Indonesia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: South Korea, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Western Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: UK, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Germany, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: France, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Italy, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Spain, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Eastern Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Russia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: North America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: USA, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: Canada, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: South America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Brazil, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Middle East, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Africa, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Pfizer Inc. Financial Performance

Table 78: Johnson & Johnson Financial Performance

Table 79: F Hoffmann La Roche Ltd. Financial Performance

Table 80: Merck & Co. Inc. Financial Performance

Table 81: AbbVie Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Branded Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Human Immunodeficiency Virus Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Human Immunodeficiency Virus Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Indonesia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: South Korea, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Western Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: UK, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Germany, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: France, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Italy, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Spain, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Eastern Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Russia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: North America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: USA, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: Canada, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: South America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Brazil, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Middle East, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Africa, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Pfizer Inc. Financial Performance

Figure 78: Johnson & Johnson Financial Performance

Figure 79: F Hoffmann La Roche Ltd. Financial Performance

Figure 80: Merck & Co. Inc. Financial Performance

Figure 81: AbbVie Inc. Financial Performance

Bell's Palsy Treatment Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Bell's Palsy Treatment Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Global Biodefense Market Projected to Reach $28.1 Billion by 2029 at a CAGR of 8.6%

$36.85 Billion Forecast for Bioelectric Medicine Market by 2029, Backed by Demand and Innovation

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Explore the latest trends, growth insights, and forecasts in the Nutrition Analysis Software Global Market.

Explore the latest trends, growth insights, and forecasts in the Global Wearable Fitness Trackers Market.

Antiviral Combination Therapy Global Market Report 2025 – By Type (Branded, Generic), By Drug Combination (Nucleotide Reverse Transcriptase Inhibitors/Non-Nucleotide Reverse Transcriptase Inhibitors, Integrase Inhibitor/...

Infectious Disease Therapeutics Global Market Report 2025 – By Type (Drugs, Vaccines), By Disease (Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases), By End-User (Hospitals And Clinics, Retail Pharmacies, Res...

Human Immunodeficiency Virus (HIV) Diagnosis Global Market Report 2025 – By Product (Consumables, Instruments, Software And Services), By Mode (Self-Test, Lab-Based), By End User (Diagnostic Laboratories, Hospitals, Rese...

Antivirals Global Market Report 2025 – By Type (Branded, Generic), By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes), By Applic...

Oncolytic Virus Therapy Global Market Report 2025 – By Therapy Type (HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types),...

Hepatitis Therapeutics Global Market Report 2025 – By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types), By Drug Class (Oral Antivirals, Immune Modulators), By Distribution Channel (Hospital Pharm...

Anti-Infective Drugs Market - By Type (Antibiotics, Antivirals, Antifungals), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classifi...

Frequently Asked Questions

What is the definition of the Human Immunodeficiency Virus Therapeutics market?

How will the Human Immunodeficiency Virus Therapeutics market drivers and restraints affect the market dynamics? What forces will shape the Human Immunodeficiency Virus Therapeutics industry going forward?

The market major growth driver - Increase In Unprotected Sexual Practices Fueling The Market Due To Limited Access To Contraception And Lack Of Comprehensive Sex Education. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Human Immunodeficiency Virus Therapeutics market?

The human immunodeficiency virus therapeutics market size has grown strongly in recent years. It will grow from $14.11 billion in 2024 to $14.9 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rise in HIV prevalence, growth in awareness programs, rise in diagnostic testing, growth in generic drug penetration, and rise in healthcare infrastructure. The human immunodeficiency virus therapeutics market size is expected to see strong growth in the next few years. It will grow to " $18.44 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising HIV patient pool, increasing HIV screening, increase in voluntary testing, surge in unprotected sex practices, and expansion of government programs. Major trends in the forecast period include technological advancements, AI-driven drug discovery, long-acting injectable therapies, telemedicine integration, and CRISPR-based gene therapy. For further insights on this market, request a sample here

How is the Human Immunodeficiency Virus Therapeutics market segmented?

The human immunodeficiency virus therapeuticsmarket covered in this report is segmented –
1) By Drug Type: Branded Drugs; Generic Drugs
2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis); Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis); Entry And Fusion Inhibitors; Protease Inhibitors (Pis); Integrase Inhibitors; Coreceptor Antagonists
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
4) By End-user: Hospitals And Clinics; Specialty Centers Subsegments:
1) By Branded Drugs: Biktarvy; Triumeq; Genvoya; Juluca; Dovato; Isentress; Prezista
2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF); Lamivudine; Efavirenz; Zidovudine; Nevirapine; Abacavir; Ritonavir For further insights on this market, request a sample here

Which region has the largest share of the Human Immunodeficiency Virus Therapeutics market? What are the other regions covered in the report?

North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Human Immunodeficiency Virus Therapeutics market?

What are the key trends in the Human Immunodeficiency Virus Therapeutics market?

Major trends in this market include Focus On Combination Therapy For Improved Treatment Outcomes. For further insights on this market, request a sample here.